Company intelligence / Profile preview

Nakima

Thousand Oaks, California, USA

Ownership: Private
Development stage: Other

Overview

Nakima Therapeutics is a stealth-mode biotechnology company focused on developing novel small molecule inhibitors for the treatment of cancer. The company's primary research centers on targeting Nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in the NAD+ salvage pathway that is frequently overexpressed in various malignancies. By inhibiting NAMPT, Nakima aims to disrupt the metabolic processes of cancer cells, leading to NAD+ depletion and subsequent cell death. Founded and backed by Westlake Village BioPartners, the company is currently advancing its lead programs through pre-clinical development. The company is headquartered in Thousand Oaks, California, and operates within the precision oncology space.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Westlake Village BioPartners

Beyond the preview

Go deeper on Nakima.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nakima.

Explore the full profile